People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

11 Oct 2019
Change (% chg)

$0.75 (+1.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Carter, Bruce 

Dr. Bruce L.A. Carter, Ph.D., is Independent Chairman of the Board of the Company. He has served on our Board of Directors since November 2013 and as our Chairman of the Board since December 2015. Dr. Carter is an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He served as Executive Chairman of Immune Design Corp., a privately held biotechnology company, from November 2009 to November 2011 and he served as a director from 2000 to January 2009. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a publicly-held biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1998, Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a publicly-held pharmaceutical company. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. Dr. Carter serves as a director of Dr. Reddy’s Laboratories Limited, a publicly-held pharmaceutical company, and Xencor, Inc. and Mirati Therapeutics, publicly-held biopharmaceutical companies. Dr. Carter holds a Ph.D. in microbiology from Queen Elizabeth College, University of London and a B.Sc. with Honors in botany from the University of Nottingham, England.

Basic Compensation

Total Annual Compensation, USD 87,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 306,690
Fiscal Year Total, USD 394,190

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bruce Carter


Jay Luly


Paul Mellett


Yat Sun Or


Nathaniel Gardiner


Nathalie Adda

As Of  30 Sep 2018